Q2 2018 EPS Estimates for Insulet Corporation Increased by Northcoast Research (PODD)

Insulet Corporation (NASDAQ:PODD) – Equities research analysts at Northcoast Research upped their Q2 2018 earnings per share (EPS) estimates for shares of Insulet Corporation in a report issued on Friday. Northcoast Research analyst E. Snyder now forecasts that the medical instruments supplier will earn $0.00 per share for the quarter, up from their prior forecast of ($0.01).

Insulet Corporation (NASDAQ:PODD) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $110 million during the quarter, compared to analysts’ expectations of $106.23 million. Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) earnings per share.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2017/08/19/q2-2018-eps-estimates-for-insulet-corporation-increased-by-northcoast-research-podd-updated.html.

Several other brokerages also recently weighed in on PODD. B. Riley reissued a “neutral” rating and issued a $44.00 target price on shares of Insulet Corporation in a research note on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $55.00 target price on shares of Insulet Corporation and gave the company a “hold” rating in a research note on Friday, August 4th. Jefferies Group LLC reissued a “buy” rating and issued a $58.00 target price (up previously from $48.00) on shares of Insulet Corporation in a research note on Wednesday. Northland Securities reissued a “buy” rating on shares of Insulet Corporation in a research note on Friday, August 4th. Finally, Cowen and Company reissued an “outperform” rating and issued a $63.00 target price (up previously from $52.00) on shares of Insulet Corporation in a research note on Friday, August 4th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $50.46.

Shares of Insulet Corporation (NASDAQ PODD) traded down 1.691% during midday trading on Monday, hitting $53.785. 123,351 shares of the stock were exchanged. Insulet Corporation has a 12-month low of $30.69 and a 12-month high of $55.46. The firm’s market cap is $3.12 billion. The firm has a 50-day moving average price of $50.48 and a 200 day moving average price of $44.77.

Several hedge funds have recently modified their holdings of PODD. Granite Investment Partners LLC increased its position in Insulet Corporation by 0.4% in the second quarter. Granite Investment Partners LLC now owns 19,502 shares of the medical instruments supplier’s stock valued at $1,001,000 after buying an additional 76 shares during the period. Principal Financial Group Inc. increased its position in Insulet Corporation by 1.1% in the first quarter. Principal Financial Group Inc. now owns 8,171 shares of the medical instruments supplier’s stock valued at $352,000 after buying an additional 92 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Insulet Corporation by 11.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after buying an additional 235 shares during the period. Legal & General Group Plc increased its position in Insulet Corporation by 1.9% in the second quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock valued at $1,034,000 after buying an additional 376 shares during the period. Finally, Geneva Advisors LLC increased its position in Insulet Corporation by 2.3% in the second quarter. Geneva Advisors LLC now owns 22,215 shares of the medical instruments supplier’s stock valued at $1,140,000 after buying an additional 504 shares during the period.

In other news, SVP Michael P. Spears bought 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was acquired at an average price of $40.59 per share, for a total transaction of $101,475.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Bradley A. Thomas bought 3,000 shares of the firm’s stock in a transaction dated Thursday, May 11th. The shares were purchased at an average price of $38.69 per share, with a total value of $116,070.00. The disclosure for this purchase can be found here. Insiders have bought a total of 8,080 shares of company stock valued at $317,339 in the last quarter. Company insiders own 2.60% of the company’s stock.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Earnings History and Estimates for Insulet Corporation (NASDAQ:PODD)

What are top analysts saying about Insulet Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insulet Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit